DraftUnitedHealthcarePolicy CS007NE.U

Bariatric Surgery (for Nebraska Only)

Defines medical necessity, coverage stance, and coding guidance for bariatric surgical procedures for members in Nebraska; applies to providers performing bariatric surgery within the State of Nebraska.

Policy Summary

PayerUnitedHealthcare

PolicyBariatric Surgery (for Nebraska Only)

Policy CodePolicy CS007NE.U

Change TypeMaterial revisions and code updates

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization and document BMI, prior procedures, multidisciplinary assessment, and conservative therapy attempts when requesting coverage for bariatric or revisional procedures.

SourceLink

POLICY UPDATE CHANGES

Replaced language indicating revisional bariatric surgery using specific listed procedures is proven and medically necessary when due to technical failure or major complication with streamlined language that revisional bariatric surgery is proven and medically necessary when due to a technical failure or major complication from the initial procedure.

Removed prior explicit list of proven and medically necessary bariatric procedures (adjustable gastric banding, sleeve gastrectomy, vertical banded gastroplasty) and the detailed adult/adolescent BMI and comorbidity coverage language.

Added CPT codes 43999 and 64999 to the applicable codes list.

Updated supporting sections: Description of Services, Clinical Evidence, FDA, and References to reflect current information and archived previous policy version CS007NE.T.

Updated related policy link/title for Minimally Invasive Procedures for Gastric and Esophageal Diseases (for Nebraska Only).

Nebraska-onlypolicy application

BMI ≥50planned two-stage BMI

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Second stage ≤2ytwo-stage timing

LA Grade C/Desophagitis severity

43775recommended CPT example

6 monthsIGB usual duration

Coverage Criteria for Bariatric & Obesity Management

Bariatric Artery Embolization (BAE)

Bariatric artery embolization (BAE) — investigational

ALL of the following

Bariatric artery embolization (percutaneous trans‑arterial embolization targeting the left gastric artery) is considered investigational due to insufficient evidence of durable safety and long‑term efficacy.
Available randomized and nonrandomized studies report modest short‑term weight loss but are limited by small sample sizes, single‑center designs, high attrition, and lack of long‑term follow‑up; meaningful clinical benefit and safety beyond 12 months remain unproven.
Well‑designed randomized controlled trials with adequate sample size, standardized technique, blinded assessment, and extended follow‑up are required to establish efficacy and safety.

Gastric Electrical Stimulation (GES)

Gastric electrical stimulation (GES) — investigational

ALL of the following

Implantable gastric electrical stimulation devices for weight loss are considered investigational because current evidence is inadequate to demonstrate consistent, durable clinical benefit and long‑term safety.
Early feasibility studies and small prospective cohorts show weight loss in some participants at 12–24 months, but trials are limited by small sizes, lack of adequate control arms, heterogeneity in devices and settings, and short or incomplete follow‑up.
Larger randomized controlled trials with standardized device parameters, long‑term outcomes, and safety monitoring are needed before GES can be considered medically necessary for obesity management.

Intragastric Balloon (IGB)

Intragastric balloon (IGB) — short‑term efficacy with uncertain long‑term benefit

ALL of the following

Intragastric balloons (endoscopically placed or ingestible) produce clinically significant short‑term weight loss when used with diet and behavior modification, typically while the device is in place (commonly up to 6 months).
Available randomized trials and registries demonstrate superior weight loss versus diet alone during the treatment period, but evidence for sustained long‑term weight maintenance after balloon removal is limited and mixed.
Studies report notable rates of nonserious adverse events and some serious events (e.g., ulceration, early removal, rare migrations/obstructions); reporting and follow‑up completeness vary across studies.
Given the temporary nature of the device, effectiveness for chronic weight management depends on concurrent and sustained multidisciplinary behavioral and medical support; current evidence does not establish durable, long‑term benefit for most patients.

Laparoscopic Greater Curvature Plication (LGCP)

Laparoscopic greater curvature plication (LGCP) — limited and mixed evidence

ALL of the following

Laparoscopic greater curvature plication (LGCP) has limited high‑quality evidence and mixed outcomes when compared with established bariatric procedures such as laparoscopic sleeve gastrectomy (LSG).
Randomized and observational studies suggest comparable short‑term weight loss but inferior durability of weight loss and higher adverse event or revision rates in some series at mid‑ to long‑term follow‑up (≥2 years).
Evidence is heterogeneous, often single‑center, with variable follow‑up and substantial risk of bias; therefore LGCP remains investigational or not routinely medically necessary as a primary durable bariatric procedure pending more robust long‑term comparative data.

Provider Actions, Prior Authorization & Documentation Requirements

Prior Authorization

Prior authorization required for revisional bariatric surgery

Prior authorization is required for revisional bariatric surgery. Prior to authorization the provider must document the prior index procedure, the specific indication for revision (e.g., technical failure, major complication), and evidence that less invasive corrective measures were attempted when applicable (for adjustable gastric banding, records must demonstrate attempted manipulation/adjustment). A multidisciplinary assessment documenting individualized risks/benefits and confirmation that the failure is anatomic (not solely behavioral) is required.

Confirm prior index procedure and operative details (type, date, intraoperative conversions).
Document indication for revision (conversion, corrective, or reversal) and objective findings (imaging, endoscopy, labs).
Provide evidence of attempted non-surgical management when applicable (e.g., band manipulation/adjustment).
Include multidisciplinary assessment (surgeon, nutritionist, behavioral health, as appropriate).

Prior Authorization

IGB prior authorization: failed non‑surgical therapy and behavioral program required

Applicable Procedure and Device Codes

Applicable procedure codesCPT

0813T	Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon.
43290	Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon.
43291	Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s).
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less).
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption.
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (e.g., gastric band and subcutaneous port components).
43771	Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only.

1–10 of 30

1/3

Device approvals and indications (no billing codes provided)mixed

Not specified

FDA approvals and indications described for devices (e.g., ORBERA intragastric balloon system, LAP-BAND, TransPyloric Shuttle, OverStitch) without explicit billing codes listed in this section.

Added CPT codesCPT

43999	Unlisted procedure, stomach
64999	Unlisted procedure, nervous system (added)

inv-40: BMI thresholds — planned two-stage and general obesity classifications

Planned two‑stage thresholdInitial BMI ≥ 50 kg/m2 prior to first‑stage bariatric procedure; second stage must occur within 2 years

Obesity class IBMI 30.0–34.9 kg/m2

Obesity class IIBMI 35.0–39.9 kg/m2

Obesity class IIIBMI ≥ 40.0 kg/m2

inv-41: BMI thresholds — guideline-based class definitions and ancestry adjustments

Class III (guideline definition)BMI ≥ 40 kg/m2

Background and Evidence Summary

Obesity is defined clinically using the body mass index (BMI) and is associated with multiple comorbid conditions including hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, and certain cancers. Metabolic and bariatric surgery aims to produce substantial and sustained weight loss and to improve obesity-related comorbidities; procedures may be restrictive, malabsorptive, or both, and require multidisciplinary assessment for candidate selection.

Adolescent surgical candidates require additional considerations such as growth/pubertal status and multidisciplinary evaluation by experienced centers.

inv-05: Revisional Bariatric Surgery — evidence summary (duplicated in background for context)

When considering revisional bariatric surgery, the following candidate criteria must ALL be documented:

Multidisciplinary support and documentation: 1) Documented indication for revision (anatomic complication, device failure, leak, obstruction, persistent or recurrent severe symptoms, or inadequate weight loss/clinically significant weight regain) AND 2) Thorough multidisciplinary evaluation (surgical, nutritional, behavioral/psychosocial assessment) with documentation that behavioral contributors were addressed or ruled out AND 3) Individualized risk–benefit assessment with documentation of center and surgeon expertise (MBSAQIP accreditation considered), and plan for perioperative and long-term follow-up.

Records should include prior procedure details, imaging/endoscopic confirmation when applicable, nutrition and psychosocial evaluations, and documentation of attempts at nonoperative management when appropriate.

Definitions and Device Terms

inv-80: Body Mass Index (BMI) definition

BMI definition (formula)Body Mass Index (BMI) = weight in kilograms divided by height in meters squared

Use of BMIBMI is used clinically to classify weight status and obesity classes but is not diagnostic of body fatness or overall health

Adult BMI categories (NHLBI)<18.5 underweight; 18.5–24.9 normal; 25–29.9 overweight; 30–34.9 Obesity Class I; 35–39.9 Obesity Class II; ≥40 Obesity Class III

inv-81: Revisional Bariatric Surgery — conversion/corrective/reversal definitions

Conversion (revisional type)A second bariatric procedure that changes the bariatric approach to a different procedure type (e.g., band to RYGB)

CorrectiveProcedure that corrects or modifies anatomy of a previous bariatric procedure to achieve the original desired outcome or correct a complication

Policy Revision History and Material Changes

2025-10-01reference_update

Updated related policy link/title for 'Minimally Invasive Procedures for Gastric and Esophageal Diseases (for Nebraska Only)'.

2025-08-01material_revisionLatest

Revised revisional bariatric surgery language: replaced procedure-specific list with streamlined statement that revisional bariatric surgery is proven and medically necessary when due to a technical failure or major complication from the initial procedure; removed prior explicit list of proven procedures and detailed adult/adolescent BMI/comorbidity coverage language.

The policy revision removed previously listed proven procedures and several age-specific criteria from the coverage text. Notably, prior explicit adult/adolescent BMI and comorbidity thresholds and named procedure lists were streamlined or eliminated during this update.

Policy Summary

PayerUnitedHealthcare

PolicyBariatric Surgery (for Nebraska Only)

Policy CodePolicy CS007NE.U

Change TypeMaterial revisions and code updates

Effective DateAug 1, 2025

Next Review DateN/A

SourceLink

On This Page

IGB may be appropriate as a short‑term adjunct (e.g., bridge to surgery or to achieve rapid weight loss) in selected patients when used within a comprehensive program, but additional high‑quality RCTs with long‑term follow‑up are needed to clarify safety and durability.

Intragastric balloon (IGB) therapy requires prior authorization and documentation that conservative, non-surgical therapies failed. The request must include evidence of a supervised behavioral program and prior attempts at diet, exercise, and weight-loss medication management as appropriate.

Document history of unsuccessful conservative therapy (diet, activity, behavioral modification).
Provide evidence of enrollment and participation in a supervised diet and behavior modification program.
Record BMI within device-specific indication ranges and comorbidity status per plan criteria.

Prior Authorization

Prior authorization required for evolving endoscopic and device-based technologies

Prior authorization is required for evolving or device-based technologies (for example AspireAssist, endoscopic procedures such as ESG, Transpyloric Shuttle, gastro-intestinal liners/DJBL, and other endoscopic or implantable devices). Requests must include supporting clinical evidence, rationale for use over established therapies, and patient-specific risk/benefit discussion.

Include published evidence or trial data supporting the chosen device/procedure and why standard surgical options are not appropriate.
Provide documentation of patient counseling regarding investigational status or limited evidence for long-term safety/efficacy.
Specify device labeling/indication and planned duration of treatment (if applicable).

Prior Authorization

Authorization requires BMI and comorbidity-based documentation

Authorization for bariatric procedures requires documentation of BMI, applicable comorbidity-based indications, and completion of multidisciplinary preoperative evaluations. For adults and adolescents, provide objective measurements and supporting clinical rationale that the individual meets BMI and comorbidity thresholds per professional guidelines.

Include current BMI and documented weight history.
List obesity-related comorbidities and severity (e.g., T2D, OSA, NASH) that justify the procedure.
For adolescents, include age, Tanner stage/height attainment and guideline-based criteria as applicable.

Documentation Required

Device labeling and indication notes must be provided

Providers must document device labeling and indications for device-based therapies. Include FDA labeling details where applicable (e.g., ORBERA: adults BMI 30–40, adjunct to supervised diet/behavior program, maximum 6-month placement) and manufacturer contraindications (for example, adjustable gastric bands contraindicated in patients <18 years).

Attach or reference FDA approval/labeling or formal device instructions for use.
State device-specific age limits, placement duration, and required adjunct programs (diet/behavioral modification).

Documentation Required

Facility accreditation and staged‑procedure risks

Procedures performed outside an accredited bariatric surgery program or outside MBSAQIP-equivalent centers may not meet policy expectations. Providers should disclose facility accreditation status and recognize that staged procedures carry timing and clinical-risk considerations.

Specify facility accreditation (MBSAQIP or equivalent) in the authorization request.
For planned two-stage procedures, document initial BMI ≥ 50 kg/m2, planned interval (second stage within 2 years), and compliance with nutritional/physical therapy requirements.

Prior Authorization

Pre-revision multidisciplinary assessment required

Prior to revisional surgery, a formal pre-revision multidisciplinary assessment is required. This assessment should confirm the indication, review alternative non-surgical management (including trials for GERD management when appropriate), and document patient adherence to recommended behavioral and nutritional therapies.

Provide multidisciplinary notes (surgical, nutritional, behavioral, and any specialty consults).
Document attempts at conservative management for postoperative complications (e.g., GERD: lifestyle/dietary changes, pharmacologic therapy, and evidence of severe esophagitis if claiming failure).

Documentation Required

Revisional surgery has increased complication risk — document counseling

Providers must acknowledge and document that revisional bariatric surgery carries higher complication rates than primary procedures. Authorization requests should include risk counseling documentation and evidence that expected benefits outweigh increased perioperative and long-term risks.

Include documentation of individualized risk/benefit counseling and informed consent.
Provide data on prior complications and rationale that revision addresses technical failure or major complication rather than behavioral issues.

Denial Risk

AspireAssist / stomach aspiration — evidence insufficient; robust RCTs required

Stomach aspiration therapy (AspireAssist) currently has limited and low‑quality evidence for long‑term safety and efficacy. Prior authorization requests for aspiration therapy should include robust supporting evidence; absence of high-quality RCTs and concerns about behavioral effects or long-term outcomes may lead to noncoverage.

Provide RCT data and long-term follow-up when available.
Document why alternative, guideline-supported interventions are not appropriate for this patient.

Denial Risk

Endoscopic bariatric procedures — evidence limitations; provide trial data

Endoscopic bariatric procedures (e.g., ESG, TPS, endoscopic bypass liners) have limited or inconclusive evidence. Authorization should include available trial data, justification versus established surgical options, and plans for long-term follow up; lack of supportive evidence may result in noncoverage.

Submit peer-reviewed evidence, trial size/duration, and safety/adverse event profile.
Explain why the patient is a candidate for endoscopic approach rather than standard procedures.

Denial Risk

Safety-related coverage risk for devices with high adverse event rates

Some devices and procedures have safety concerns (e.g., DJBL with high adverse event rates). Requests involving devices with known serious adverse events must include detailed risk mitigation plans and rationale; significant safety signals may preclude coverage.

Provide full AE/SAE history for the device and patient-specific risk assessment.
Explain monitoring and contingency plans for potential device-related complications.

Documentation Required

Contraindications per Endocrine Society and professional guidance

Follow professional society contraindications: do not perform bariatric surgery in preadolescent children, pregnant or breastfeeding adolescents, or patients with unresolved substance abuse, active eating disorders, or untreated psychiatric illness. Authorization should reflect adherence to these contraindications.

For pediatric/adolescent requests, document Tanner stage, growth status, and psychological stability.
Confirm absence of pregnancy and pregnancy planning within 2 years when applicable.

Prior Authorization

Verify member benefits and contractual/federal/state coverage rules

Benefit plan verification is required. Coverage determinations must align with the member's federal, state, or contractual benefit terms; inclusion of a procedure in this policy does not guarantee coverage under every plan.

Verify member benefits and any state- or contract-specific mandates prior to authorization submission.
If plan terms differ from this policy, the applicable contractual/federal/state requirements govern.

Documentation Required

Required clinical documentation for authorization

Required clinical documentation for authorization includes a detailed obesity-focused history, current and historical BMI values, weight trends, prior weight-loss attempts (commercial programs, prescriptions), and documentation of prior device manipulations/adjustments or severity of esophagitis when relevant.

Provide detailed weight history and prior conservative therapy attempts (diet, exercise, medications).
For adjustable band issues, include records of attempted band manipulation/adjustment.
Include endoscopy reports grading esophagitis (e.g., Los Angeles classification) when reflux is an indication for revision.

Documentation Required

Required documentation specific to revisional bariatric surgery

When requesting revision surgery, include documentation of the prior index procedure (operative report), reason for revision (technical failure, leak, obstruction, erosion, staple-line failure, uncontrollable reflux), and objective diagnostic evidence (imaging, endoscopy, labs).

Attach prior operative report and prior procedure details.
Include imaging or endoscopic confirmation of the complication prompting revision.
Document prior non-surgical management and multidisciplinary recommendations.

Documentation Required

Trial and evidence documentation required for vagus nerve blocking therapies

For vagus nerve blocking (vBloc) or similar neuromodulation therapies, provide trial documentation and published outcome data. Given limited long-term effectiveness evidence, authorization requires demonstration that the patient met trial inclusion criteria and failed conservative therapies.

Submit pivotal trial references (e.g., ReCharge study) and patient-level applicability.
Document prior conservative therapy failure and qualifying BMI/comorbidity criteria used in trials.

Documentation Required

Nutritional screening and postoperative monitoring documentation required

Nutritional documentation is required pre- and post-operatively. Providers must document preoperative micronutrient screening, a postoperative monitoring plan, and the involvement of a registered dietitian or nutritionist in care planning.

Provide baseline micronutrient labs and plan for serial monitoring.
Include documentation of planned dietary follow-up and nutritionist involvement.

Documentation Required

Preoperative and postoperative education and monitoring must be documented

Preoperative education and postoperative follow-up plans must be documented. Authorization requests should include evidence of patient education on expected nutrient deficiencies, required lifestyle changes, and the postoperative monitoring and support plan.

Include evidence of preoperative counseling on nutrition, activity, and expected outcomes.
Provide the postoperative follow-up schedule and behavioral health resources available to the patient.

Documentation Required

Preoperative psychosocial evaluation required

Preoperative psychosocial evaluation is required. Document evaluation by a licensed behavioral health professional experienced in bariatric care and include assessment of psychiatric stability, substance use, eating disorders, motivation, and family support.

Attach psychosocial evaluation and any recommendations or requirements for preoperative stabilization.
For adolescents, include documentation that psychological evaluation confirms family stability and patient competence.

Step Therapy

Conservative therapy required and must be documented prior to intervention

Conservative therapy (dietary, activity, behavior modification, and medication management) should be attempted and documented prior to most bariatric interventions unless clinically contraindicated. For revisional procedures, a trial of non-surgical management for postoperative issues (e.g., GERD) is expected prior to revision.

Document supervised diet/exercise programs and any pharmacologic weight-loss therapies tried.
For GERD after sleeve gastrectomy, document trials of positional and dietary changes, double-dose PPI/H2 blocker for at least one month, and endoscopic confirmation of severe esophagitis if claiming failure.

Documentation Required

Stepwise treatment history and adolescent-specific documentation

Stepwise treatment documentation should summarize prior medical, behavioral, device, or surgical interventions and show the rationale for escalation to the requested procedure. For adolescents include documentation of formal lifestyle modification and psychological evaluation.

Provide a chronology of prior treatments and outcomes (medical, behavioral, procedural).
For adolescents, include documentation of formal programs and psychosocial readiness.

Class II (guideline definition)BMI 35.0–39.9 kg/m2 (typically with at least one severe obesity‑related complication)

Consideration at lower BMISelect patients with BMI 30.0–34.9 kg/m2 and inadequately controlled T2D may be considered per some guidelines; ancestry‑adjusted thresholds apply (see note)

Ancestry adjustment exampleFor patients of Asian descent, reduce BMI thresholds by ~2.5 kg/m2 per guideline recommendations

inv-42: BMI thresholds — adult/adolescent thresholds and guideline nuances

Adult MBS indication (general)MBS recommended for individuals with BMI ≥ 35 kg/m2; consider for BMI 30.0–34.9 kg/m2 with metabolic disease

ADA diabetes guidanceConsider metabolic surgery for individuals with diabetes and BMI ≥ 30.0 kg/m2 (≥27.5 kg/m2 in Asian American individuals)

Pediatric/adolescent thresholdsRecommend MBS for patients ≥12 years with Class II (BMI ≥35 or 120% of 95th percentile with clinically significant disease) or Class III (BMI ≥40 or 140% of 95th percentile)

inv-43: BMI thresholds — device-specific labeled indications (ORBERA, LAP-BAND historical)

ORBERA labeled indicationORBERA indicated as adjunct to weight reduction in adults with BMI ≥ 30 and ≤ 40 kg/m2; maximum placement period of 6 months

LAP‑BAND (historical labeling)LAP‑BAND approved for adults with BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 with one or more severe comorbid conditions; 2011 approval extended to BMI ≥ 30 kg/m2 with ≥1 obesity‑related comorbidity in some labeling

inv-44: BMI and comorbidity thresholds (previously listed) — removed thresholds from this policy version

Previously listed explicit adult thresholds removedPrior explicit policy language specifying adult thresholds (e.g., BMI ≥40 or BMI ≥35 with comorbidities) was removed from this policy version

Previously listed adolescent thresholds removedDetailed age‑specific BMI and comorbidity coverage language for adolescents was removed from this version

Definitions removedDefinitions for Asian, Multidisciplinary, NAFLD, and OSA were removed from the prior policy text

The policy reiterates that evidence for many device-based and endoscopic bariatric treatments is limited in quality and duration; while some modalities show short-term weight loss, the long-term efficacy and comparative effectiveness versus established surgical procedures are not well supported.

This lack of robust long-term data informs the policy’s investigational stance for many evolving bariatric devices and endoscopic therapies.

Randomized controlled trials and meta-analyses comparing LGCP with LSG demonstrate that LGCP has inferior durability of weight loss and is associated with higher adverse event rates. These comparative data support a policy position that LGCP is not an evidence-based alternative to LSG for durable weight-loss outcomes.

The ASMBS position statement clarifies that mandated preoperative supervised weight loss lacks high-level evidence (no RCTs or Level I data) and therefore preoperative weight-loss mandates should not be required as a blanket prerequisite for surgery; candidacy and preoperative preparation should be individualized.

ReversalProcedure that restores original anatomy

inv-82: Transpyloric Shuttle (TPS) definition

TPS descriptionTranspyloric Shuttle (TPS) is a non‑balloon, space‑occupying endoscopic device comprising two silicone bulbs connected by a tether delivered and removed endoscopically

FDA approval and durationFDA premarket approval granted April 16, 2019 for treatment up to 12 months in specified BMI ranges

Adjunctive useIntended to be used in conjunction with diet and behavior modification programs

inv-83: Intragastric balloon (IGB) definition

IGB mechanismIntragastric balloons are acid‑resistant balloons inserted and expanded in the stomach to promote early satiety as an adjunct to diet, exercise, and behavioral counseling

Typical durationAvailable data and manufacturer recommendations indicate ~6 months is the current standard duration from insertion to removal

Adjunctive programDevices are intended to be used alongside long‑term supervised diet and behavior modification programs

inv-84: Laparoscopic Greater Curvature Plication (LGCP) definition

LGCP procedureLaparoscopic greater curvature plication (LGCP) folds and sutures the stomach onto itself to reduce gastric volume without resection, bypass, or implant

Relation to sleeve gastrectomyLGCP is a modification of sleeve gastrectomy but does not involve gastric resection

Evidence noteEvidence is limited and mixed, with reports of weight regain and need for revisional surgery in some series

inv-85: Stomach aspiration therapy (AspireAssist) definition

AspireAssist descriptionStomach aspiration therapy (AspireAssist) uses a surgically placed endoluminal tube to aspirate a portion of gastric contents after meals as an adjunct to lifestyle therapy

Intended useIntended for long‑term use in conjunction with lifestyle therapy and continuous medical monitoring

Safety/monitoringRegular monitoring required for weight progress, stoma site health, and metabolic/electrolyte balance

inv-86: Revisional bariatric surgery definition (general)

General revisional surgery definitionSurgical procedures performed after a prior bariatric operation to address complications, inadequate weight loss, or weight regain (including conversions, corrective procedures, or reversals)

Indications examplesExamples include conversion for failed primary procedure, correction of anatomical complications, and restoration of anatomy for reversal

Risk noteRevisional procedures have higher reported complication rates compared with primary procedures

inv-87: Bariatric artery embolization (BAE) definition

BAE descriptionBariatric artery embolization (BAE) is transcatheter embolization of gastric arteries (commonly the left gastric artery) intended to reduce ghrelin and promote weight loss

Evidence statusCurrently investigational with limited RCT and case‑series data; additional robust RCTs and long‑term follow‑up are warranted

inv-88: Gastric electrical stimulation (GES) definition

GES descriptionGastric electrical stimulation (GES) is an implantable device delivering electrical pulses to the stomach to modify motility and satiety

Evidence statusEarly‑phase and small studies report mixed results; larger, well‑designed RCTs with long‑term follow‑up are needed

inv-89: Intragastric balloon (IGB) definition (expanded)

IGB (expanded) mechanism and intentIntragastric balloons occupy gastric volume to promote satiety as a temporary obesity treatment and are intended as adjuncts to diet, exercise, and behavioral counseling

Duration and device variabilityDevice‑specific evidence varies; most clinical data use balloons for ~6 months, and long‑term weight maintenance after removal is uncertain

Safety noteIGBs are associated with frequent adverse events and require monitoring; long‑term efficacy and safety remain uncertain

inv-90: LGCP definition (additional)

LGCP additional detailLGCP reduces gastric volume by plicating the greater curvature; reported metabolic improvements but may be less effective than sleeve gastrectomy due to preservation of secretory regions

Outcomes variabilitySome cohorts report durable excess BMI loss at 5 years, while others report high rates of weight regain and revision

inv-91: LGCP definition (duplicate entry)

LGCP duplicate noteLGCP is a restrictive plication procedure that requires no resection or implant and has limited, mixed evidence regarding long‑term durability

TerminologyAlso known as Total Gastric Vertical Plication (TGVP)

inv-92: Aspiration Therapy (AspireAssist) definition (expanded)

Aspiration therapy expandedAspiration therapy (AspireAssist) employs a percutaneous gastrostomy‑based system enabling aspiration of gastric contents after meals with reported clinically significant weight loss in limited studies

SAE rateSystematic review/meta‑analysis reported pooled serious adverse event rate ~4.1%

Long‑term dataEvidence is limited by small, observational studies; larger RCTs with long‑term follow‑up are needed

inv-93: Transoral endoscopic devices / TPS definition (expanded)

Transoral endoscopic devices (expanded)Includes endoluminal devices placed endoscopically (e.g., TPS) to alter gastric physiology or bypass; feasibility and small trials show weight loss but evidence is limited and longer‑term safety/efficacy data are needed

TPS specificsTPS consists of two silicone bulbs joined by a tether; studied treatment durations include up to 12 months with FDA approval for defined BMI ranges

inv-94: Endoscopic Sleeve Gastroplasty (ESG) definition

ESG definitionEndoscopic sleeve gastroplasty (ESG) uses endoscopic suturing (e.g., OverStitch) to reduce gastric capacity as a less‑invasive alternative to surgical sleeve gastrectomy

Evidence snapshotRCTs and observational data show modest %TBWL versus LSG with limited long‑term comparative evidence

inv-95: Vagus Nerve Blocking (vBloc / Maestro) definition

vBloc/Maestro descriptionVagus nerve blocking (vBloc/Maestro) is an implantable neuroregulator that intermittently blocks vagal signaling to affect satiety and weight

Trial evidencePivotal randomized trials (ReCharge) show modest weight loss versus sham but failed to meet some prespecified coprimary efficacy objectives; safety endpoints were met

inv-96: Class II/III obesity and indications definition

Class II/III obesity definitionsClass III: BMI ≥ 40 kg/m2; Class II: BMI 35.0–39.9 kg/m2 (often with inadequately controlled hyperglycemia or other severe obesity‑related complications)

Consideration at BMI 30–34.9Some guidelines consider patients with BMI 30.0–34.9 kg/m2 and type 2 diabetes for MBS

inv-97: MBS Indication BMI — thresholds definition

MBS adult BMI indication (ASMBS/IFSO)MBS recommended for individuals with BMI ≥ 35 kg/m2; should be considered for BMI 30.0–34.9 kg/m2 with metabolic disease

Ancestry adjustmentFor Asian populations, BMI ≥ 25 kg/m2 suggests clinical obesity and BMI ≥ 27.5 kg/m2 should be offered MBS

inv-98: SADI-S / SADS definition

SADI‑S / SADS definitionSingle‑anastomosis duodeno‑ileal bypass with sleeve gastrectomy (SADI‑S/SADS) — a bariatric procedure with evidence of weight loss and T2D control but limited long‑term data and nutritional deficiency risk

Evidence noteIFSO review found limited high‑quality long‑term evidence and encouraged registry participation and RCTs

inv-99: EndoBarrier (DJBL) definition

EndoBarrier descriptionEndoBarrier (duodenal‑jejunal bypass liner) is an implantable gastrointestinal liner intended to manage T2D and obesity

Regulatory/research statusNICE and regulators note limited evidence; FDA granted an IDE in 2018 and NICE recommends use only in research or special arrangements

inv-100: ORBERA intragastric balloon definition and labeling

ORBERA system label summaryORBERA Intragastric Balloon System indicated as adjunct to weight reduction in adults with BMI ≥ 30 and ≤ 40 kg/m2; to be used with long‑term supervised diet and behavior modification; maximum placement period 6 months

Intended patient populationAdults who have failed conservative weight‑reduction strategies

inv-101: MBSAQIP definition

MBSAQIP definitionMetabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)

Role in policyAccreditation and center capability (e.g., MBSAQIP) should be considered when evaluating candidates for revisional bariatric surgery

These changes are recorded in the Policy History/Revision Information and providers should reference the updated policy language for current eligibility and documentation expectations.

Administrative coding updates in this version added CPT codes 43999 and 64999 to the applicable-procedure code list. Prior authorization requirements continue to apply per UnitedHealthcare plan and contract and these newly listed unlisted codes are subject to usual authorization processes.

Providers should use the policy’s applicable code list and follow prior authorization guidance when submitting requests that use unlisted procedure codes.